查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
創造新機會：雙特異性/多特異性藥物市場
年間契約型資訊服務
商品編碼
1876162

創造新機會：雙特異性/多特異性藥物市場

Unlocking Opportunity: Dominate the Bi/Multispecific Drug Market with Confidence
出版日期: 年間契約型資訊服務 | 出版商: BioSeeker Group AB | 英文

價格
簡介目錄

雙特異性/多特異性藥物正在革新癌症治療，開啟精準治療、免疫活化和治療潛力的新篇章。然而，在快速發展、激烈競爭和不斷擴充的研發管線中，保持領先地位需要的不僅是洞察力，更需要前沿知識、策略遠見和數據驅動的決策。

僅在2024/25年度，腫瘤藥物研發管線就將迎來創新浪潮，屆時將有278種新型雙特異性/多特異性藥物、超過800種事件驅動型藥物、8566個事件以及2120個藥物項目——這清晰地表明了該領域發展速度的加快和復雜性的增加。

隆重推出“腫瘤雙特異性/多特異性藥物分析工具”，這是一個全面的解決方案，旨在幫助您駕馭這一充滿活力的領域，追踪新興趨勢，並把握突破性機會。

探索該領域的終極工具：

  • 雙標靶/多標靶療法：以前所未有的方式克服腫瘤異質性和抗藥性
  • 下一代藥物設計：蛋白質工程、免疫調節和檢查點標靶的創新正在重塑癌症治療
  • 個人化醫療的未來：雙標靶/多標靶療法正在推動向個人化精準癌症治療的轉變
  • 前所未有的市場成長：隨著研發管線的快速擴張，現在正是投資變革性腫瘤解決方案的最佳時機

影響是什麼？快速擴張的臨床研發管線、突破性的FDA批准以及投資機會的激增，使雙標靶/多標靶療法領域成為當今癌症治療領域最令人興奮的前沿領域之一。

六大突破性優勢：

"腫瘤雙特異性/多特異性藥物分析工具" 的功能

  • 競爭格局追蹤 - 監測活躍的機構、新藥、目標分子和技術
  • 加速許可和合作 - 接觸領先的生物技術開發商、業務拓展和許可聯繫人以及學術項目
  • 增強高影響力報告和演示 - 利用近乎即時的市場情報支援數據驅動的決策。將所有資料匯出為預置的圖表和表格。
  • 與關鍵意見領袖 (KOL) 互動 - 與領先的臨床和科學專家建立聯繫。
  • 尋找合適的投資者 - 利用我們專注於腫瘤領域的融資夥伴網絡。
  • 掌握產業動態 - 分析全球主要腫瘤學會議（AACR、ASCO、ESMO、ASH 等）的資料。

我們的腫瘤雙標靶和多標靶分析工具透過持續更新和每月電子郵件提醒來保持最新狀態。

觸手可及數千種藥物、標靶、公司、臨床試驗、交易等資訊。

支持與靈感

將我們的專業知識轉化為您的虛擬業務拓展團隊。我們提供全天候 (24/7) 支持，並透過我們豐富的操作指南影片庫提供經過驗證的最佳實踐。從競爭對手產品線分析到用戶提交的真實案例研究，您將找到可操作的見解來改進您的工作。

與您共同成長的工具：

與僅提供時間快照的靜態報告不同，我們的分析工具提供一年的線上存取權限，包括近乎即時的更新、新功能、產品線提醒和專屬支援。當您想要更進一步時，可以無縫續訂您的訪問權限或升級到 1stOncology，我們行業領先的全方位服務平台——您在癌症藥物研發領域的全面合作夥伴。

系統需求：

  • 基於 Web 的應用程序，與主流瀏覽器（Chrome、Firefox、Safari、Internet Explorer）
  • 需要網路連接

取得無與倫比的智慧訊息，助力腫瘤藥物研發的策略決策

該工具由屢獲殊榮的人工智慧 (AI) 增強型智慧平台提供支援，該平台擁有超過 25 年的腫瘤學專業知識，可在腫瘤藥物研發的各個階段提供無與倫比的全面業務、競爭和臨床智慧資訊。

在業務拓展和發現/評估方面，它提供了對全球腫瘤領域無與倫比的洞察力，涵蓋從技術、靶點和新創公司到製藥公司、學術和商業機會，並作為一個強大的交易資料庫，整合了許可資訊和數千筆歷史交易。

在臨床開發方面，我們擁有業界領先的超過3000種生物標記情報庫，追蹤它們作為分層、預測和藥效學標記物的作用，同時涵蓋從早期到獲批的伴隨診斷工作。我們獨特的早期成功/失敗指標清晰地突出了臨床開發領域的領先者和落後者，使我們能夠監測和預測不斷變化的環境。

我們的臨床試驗情報不僅限於終點，還涵蓋給藥細節、抗藥性機制、不良事件、食物影響、試驗階段和進展、首次人體試驗 (FIH)、腫瘤分期/分級和治療線 (LoT)，從而提供試驗格局的全面視圖。

我們簡化了聯合療法開發的複雜性，將標靶、藥物模式、適應症和試驗階段分解，建構出不斷演進的策略圖譜，從而實現快速的策略決策。

最後，我們將真實世界數據 (RWE) 與針對每個開發階段量身定制的多方面分析相結合。我們的工具涵蓋所有區隔領域——藥物模式、聯合用藥概況、生物標記集群——能夠提供深入的背景信息，從而推動腫瘤研發領域更快、更智能、更循證的決策。

腫瘤生物製劑/多標靶藥物分析工具覆蓋範圍區隔

競爭對手概覽
監測機構數量： 超過 870 家
機構類型：
企業
私人
公立
學術機構
新創公司
癌症中心/醫院
大型製藥/生物技術		 743
435
248
89
90
38
34

五大藥物研發公司：
  • 1. 安進 (Amgen)
  • 2. 羅氏 (Hoffmann-La Roche)（含基因泰克 (Genentech)）
  • 3. 強生 (J&J)
  • 4. Xencor
  • 5.生物細胞遺傳學

排名前五的國家：
  • 1. 美國
  • 2. 中國
  • 3. 韓國
  • 4. 英國
  • 5.德國


研發管線
藥物總數：
發現
臨床前
I期
II期
III期
商業化
標靶：
腫瘤類型：
臨床試驗：
臨床生物標記：
合併用藥
療法：		 1,400+
420+
1,130+
300+
200+
23
21
481
167
1,481
464
481
167
1,481
464
197
<
合作夥伴與聯盟
過去 5 年的合約數量：
BD&L;合約：
全球學術
商業機會：		 350
超過1800
17


資金與投資者
資金（過去5年）：
主要投資者：		 1100+
231
簡介目錄

The world of bi- and multispecific drugs is transforming cancer treatment, unlocking new levels of precision, immune activation, and therapeutic potential. However, with rapid advancements, fierce competition, and an ever-expanding pipeline, staying ahead requires more than just insights - it demands up-to-date intelligence, strategic foresight, and data-driven decision-making.

In 2024/25 alone, the oncology pipeline saw a surge of innovation, with 278 new bi/multispecific drugs, over 800 drugs with events, and 8,566 total events spanning 2,120 total drug programs - a clear signal of the accelerating pace and complexity in this space.

Introducing the Bi/Multispecific Drugs in Oncology Analytical Tool - your comprehensive solution to navigate this dynamic field, track emerging trends, and capitalize on groundbreaking opportunities.

The Ultimate Tool for Exploring What Makes This Field So Exciting:

  • Dual & Multi-Targeting for Unmatched Precision: Overcome tumor heterogeneity and resistance like never before.
  • Next-Gen Drug Engineering: Innovations in protein engineering, immune modulation, and checkpoint targeting are reshaping oncology.
  • The Future of Personalized Medicine: Bi/multispecific drugs are leading the shift towards tailored, precision-based cancer therapies.
  • Unprecedented Market Growth: With a rapidly expanding pipeline, now is the time to invest in transformative oncology solutions.

The impact? A rapidly growing clinical pipeline, breakthrough FDA approvals, and a surge in investment opportunities - making the bi/multispecific field one of the most exciting frontiers in oncology today.

6 Game-Changing Benefits for You:

With the Bi/Multispecific Drugs in Oncology Analytical Tool you will:

  • Track the Competitive Landscape - monitor active organizations, new drugs, targets, and technologies
  • Accelerate Licensing & Partnerships - access top biotech developers, BD&L contacts, and academic projects
  • Power High-Impact Reports & Presentations - fuel data-driven decisions with near real-time market intelligence - all exportable in ready made graphs and tables.
  • Engage Key Opinion Leaders (KOLs) - connect with clinical and scientific experts shaping the field
  • Find the Right Investors - tap into a network of oncology-focused funding partners
  • Stay Ahead of Industry Events - analyze data from top global oncology conferences (AACR, ASCO, ESMO, ASH, and more)

Your Bi/Multispecifics in Oncology Analytical Tool is never out of date thanks to continuous updates and monthly email alerts highlighting the latest developments in the field.

You will have thousands of drugs, targets, companies, clinical trials, deals and much more at your fingertips. See below for a breakdown of our near real-time coverage.

Support & Inspiration at Your Fingertips:

Leverage our expertise as your virtual business development team-ready when you are. Our 24/7 support ensures help is always available, while our rich library of How-to Training Videos empowers you with proven best practices. From competitive pipeline analysis to real-world case studies submitted by fellow users, you'll find actionable insights designed to elevate your work.

A Tool That Grows With You:

Unlike static reports that offer just a snapshot in time, our Analytical Tools provide a full year of online access-complete with near real time updates, new features, pipeline alerts, and dedicated support. When you're ready to go further, you can seamlessly renew your access or upgrade to our industry-leading full-service platform: 1stOncology-your comprehensive partner in oncology drug development.

System Requirements:

  • Web-based application compatible with all major browsers: Chrome, Firefox, Safari, and Internet Explorer
  • Internet access

Secure Your Access to Unrivaled Intelligence for Strategic Decision-Making in Oncology Drug Development

This tool is powered by an award-winning, artificial intelligence (AI) enhanced intelligence platform with over 25 years of expertise in oncology, delivering uniquely comprehensive business, competitive and clinical intelligence across all stages of oncology drug development.

For business development and search & evaluation, it provides unmatched visibility into the global oncology landscape - spanning technologies, targets, start-ups to pharma, and academic-commercial opportunities - making it a powerful deal book with integrated licensing contacts and thousands of past deals.

In clinical development, the tool features an industry-leading biomarker intelligence panel of over 3,000 biomarkers and tracks their roles as stratifying, predictive, and pharmacodynamic markers, alongside companion diagnostic initiatives from early stage to approval. Proprietary early success/failure indicators spotlight clinical leaders and laggards, helping you monitor and and anticipate shifts in the evolving landscape.

Our clinical trial intelligence goes beyond endpoints, capturing dosage details, resistance mechanisms, adverse events, food effects, trial phase and status progression, first-in-human (FIH) studies, tumor stage/grade, and line of therapy (LoT) - offering a complete view of the trial landscape.

We simplify the complexity of combination therapy development, breaking down targets, drug modalities, indications, and trial stages to create a map of evolving strategies for fast, strategic decision-making.

Finally, we integrate Real-World Evidence (RWE) with multi-point analytics tailored to any development stage. Whether segmented by drug modality, co-medication profiles, or biomarker clusters, the tool enables deep, contextual insights - driving faster, smarter, and evidence-based decisions in oncology research and development.

Coverage Breakdown from your Bi/Multispecific Drugs in Oncology Analytical Tool

Competitor Overview
Organizations Monitored: 870+
Organization Types:
Corporate
Private
Public
Academic
Startup
Cancer Ctr/Hospital
Big Pharma/Biotech 		743
435
248
89
90
38
34

Top 5 Drug Developers:
  • 1. Amgen
  • 2. Hoffmann-La Roche (incl. Genentech)
  • 3. J&J
  • 4. Xencor
  • 5. Biocytogen

Top 5 Nations:
  • 1. USA
  • 2. China
  • 3. South Korea
  • 4. UK
  • 5. Germany


Pipeline
Total No Drugs:
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Marketed
Targets:
Tumor Types:
Clinical Trials:
Clinical Biomarkers:
Drugs in Combination Therapies: 		1,400+
420+
1,130+
300+
200+
23
21
481
167
1,481
464
197


Deals & Alliances
No. Deals (Last 5 Years):
BD&L Contacts:
World-Wide Academic
Commercial Opportunity Projects: 		350
>1,800
17


Funding & Investors
Funding (Last 5 Years):
Top Investors: 		>1,100
231